News

Deriving its name from Latin, Viatris embodies the new company’s goal of providing a path—“VIA”—to three—“TRIS”—core goals: expanding access to medicines, leading by innovating to meet patient needs,

Mavorixafor is a potential first-in-class, once-daily, oral, small molecule antagonist of chemokine receptor CXCR4, and is currently being investigated in a pivotal Phase 3 global clinical trial, 4WHIM,

The Empulse, which is the sixth phase III study in the Jardiance heart failure programme, will evaluate whether in-hospital administration of Jardiance 10mg daily enhances heart failure outcomes

Risdiplam has been designed to be a survival motor neuron-2 (SMN2) splicing modifier. The drug works by durably increasing and maintaining SMN protein levels throughout the central nervous

NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, and VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that

The scope of the deal includes the acquisition of shares in Aspen Japan and associated assets held by Aspen Global. As per terms of the deal, Aspen will

Entheogenix Biosciences Inc, the Delaware-based company jointly-founded as part of the venture, will leverage Cyclica’s proprietary technology to design and synthesize new compounds from psychoactive seed small molecule

The key investment targets of the biopharmaceutical fund of US$50 million raised is for Biosyngen biopharmaceutical technology transfer platform and to incubate companies. Biosyngen has been an angel

The submission is based on results from the Phase 3 E1912 study – designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National